{"abstract":"The National Institute of Diabetes and Digestive and Kidney Disease and National Institute of Dental and Craniofacial Research, institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an exclusive rights under active Non-exclusive Patent License to practice the inventions embodied in the United States, European and Japan Applications listed in the Supplementary Information section of this notice to Atsena Therapeutics, Inc., located in Durham, North Carolina, USA.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/11/29/2021-25873.html","cfr_references":[],"citation":"86 FR 67712","comment_url":null,"comments_close_on":"2021-12-14","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Institute of Diabetes and Digestive and Kidney Disease's Technology Advancement Office on or before December 14, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-25873","effective_on":null,"end_page":67713,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/11/29/2021-25873.xml","html_url":"https://www.federalregister.gov/documents/2021/11/29/2021-25873/prospective-grant-of-exclusivity-under-non-exclusive-patent-license-aav-isolate-and-fusion-protein","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-25873?publication_date=2021-11-29","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-11-29/2021-25873/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":119,"last_updated":"2026-04-04 20:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-11-29/pdf/2021-25873.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-25873.pdf?1637934320","publication_date":"2021-11-29","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/11/29/2021-25873.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T17:37:01Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":67712,"subtype":null,"title":"Prospective Grant of Exclusivity Under Non-Exclusive Patent License: AAV Isolate and Fusion Protein Comprising Nerve Growth Factor Signal Peptide and Parathyroid Hormone","toc_doc":"AAV Isolate and Fusion Protein Comprising Nerve Growth Factor Signal Peptide and Parathyroid Hormone","toc_subject":"Prospective Grant under Non-Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}